TQH2722

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameTQH2722
Drug Alias NameTQH-2722TQH2722BSI-045ATQC2722TQC-2722 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin-4 receptor subunit alpha
Therapy Area/IndicationsInflammationDermatitis, AtopicRhinitis, Allergic, Seasonal +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupBiosion Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co LtdNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsInflammationDermatitis, AtopicRhinitis, Allergic, Seasonal +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A